What This Immunome Sale Means a Day Before a Big FDA Milestone
Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026.
Read the full articleYou might also wanna read
CMPS Stock Climbs After-Hours: Analyst Sees Depression Drug Approval By H1 2027 Or Sooner After Strong Trial Data
The company’s rolling FDA application is underway, with final submission expected in Q4 and launch targeted for H1 2027.
Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise
Retail traders are watching to see whether ImmunityBio could announce preliminary Q2 revenue, with some speculating that demand for Anktiva
Abivax’s $920M Wall Street Haul Follows Cancer Risk Resolution, Paving Way for US Launch
Abivax clears safety concerns in ulcerative colitis trial, secures record $920M US offering, sending shares to fresh highs and setting the s
Altria Stock Is Trading Near Its High. Can It Reach New Record in 2026?
The FDA’s looser vape policy could put 200 new products on shelves, threatening the cigarette rebound behind Altria stock’s EPS growth.
Attovia Therapeutics files for Nasdaq IPO to fund immune-disease biologics
Tao Fu's San Carlos biotech is seeking an ATTO listing before disclosing price range, share count or valuation.
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials
The clearance allows the company to begin an early-stage basket trial in multiple autoimmune diseases later this year.
Comments
Sign in to join the conversation.
No comments yet. Be the first.